The firm's GI panel has also been recently evaluated in pediatric populations, demonstrating a marked increase in overall pathogen detection.
The firm also reported a 46 percent increase in molecular biology sales due to growth in its FilmArray line.
The test detects 11 viruses and three bacterial pathogens in approximately one hour and requires two minutes of hands-on time.
The study involved 11 sites and 1,560 prospectively collected patient samples and demonstrated high overall positive and negative percent agreement with comparator assays.
ISS astronauts will soon begin testing the Oxford Nanopore MinIon and two PCR platforms while researchers on Earth continue to evaluate microarrays for use in space.
On an organic basis, Q1 revenues grew more than 11 percent, driven in part by strong sales of its FilmArray, Vidas, and Vitek product portfolios.
The high-throughput system is now approved with the firm's Blood Culture ID, Gastrointestinal, Meningitis/Encephalitis, and the previously approved Respiratory Panel.
The firm has also submitted three other assays for special 510(k) clearance on the Torch system.
The FilmArray ME Panel received a de novo clearance from the US Food and Drug Administration in October.
The diagnostics company reported organic sales increased 4 percent in Q4 and 7 percent in 2015, and set a growth target of 6 percent to 8 percent for 2016.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.